Brickell Biotech, Inc. (BBI)
Stock Price:
$0.720 USD
-0.109 (-13.19%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $0.730 +0.010 (1.38%) Oct 22, 7:32 PM
Key Info
| Market Cap |
23.53M |
| Revenue (ttm) |
3.51M |
| Net Income (ttm) |
-24.87M |
| Shares Out |
32.68M |
| EPS (ttm) |
-3.17 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$0.720 |
| Previous Close |
$0.830 |
| Change ($) |
-0.109 |
| Change (%) |
-13.19% |
| Day's Open |
0.810 |
| Day's Range |
0.712 - 0.810 |
| Day's Volume |
3,021,728 |
| 52-Week Range |
0.710 - 4.110 |
More Stats
| Market Cap |
23.53M |
| Enterprise Value |
2.43M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.68M |
| Float |
29.83M |
| EPS (basic) |
-5.05 |
| EPS (diluted) |
-3.17 |
| FCF / Share |
-3.23 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
256,851 |
| Short Ratio |
0.15 |
| Short % of Float |
0.86% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.71 |
| PB Ratio |
1.25 |
| Revenue |
3.51M |
| Operating Income |
-26.12M |
| Net Income |
-24.87M |
| Free Cash Flow |
-38.16M |
| Net Cash |
21.10M |
| Net Cash / Share |
0.65 |
| Gross Margin |
-350.84% |
| Operating Margin |
-745.25% |
| Profit Margin |
-711.80% |
| FCF Margin |
-1,088.67% |
| ROA |
-104.72% |
| ROE |
n/a |
| ROIC |
-633.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.50*
(663.78% upside)
Low
5.00
Current: $0.720
High
6.00
Target: 5.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 7.92 | 10.89 | 13.82 | 14.53 | 20.95 | 15.22 | 7.72 | 17.52 | 30.02 | 8.71 |
| Revenue Growth | -27.29% | -21.21% | -4.9% | -30.64% | 37.67% | 97.16% | -55.94% | -41.64% | 244.6% | - |
| Gross Profit | 7.92 | 10.89 | 7.34 | 8.24 | 10.02 | 4.39 | -4.98 | 4.46 | 19.75 | -2.73 |
| Operating Income | -24.47 | -8.45 | -13.39 | -9.18 | -9.40 | -16.63 | -31.35 | -23.43 | -7.82 | -31.22 |
| Net Income | -23.88 | -9.24 | -12.96 | -8.97 | -9.24 | -16.49 | -31.24 | -22.90 | -7.28 | -30.39 |
| Shares Outstanding | 3.02 | 0.59 | 1.84 | 1.43 | 1.31 | 1.27 | 1.24 | 1.23 | 1.03 | 0.86 |
| Earnings Per Share | -4.50 | -25.85 | -7.07 | -6.30 | -7.07 | -13.02 | -25.20 | -18.90 | -7.00 | -35.70 |
| Operating Cash Flow | -35.98 | 3.97 | -8.60 | -8.39 | -6.95 | -9.81 | -29.80 | -17.23 | -3.64 | -28.23 |
| Capital Expenditures | -0.01 | -0.01 | -0.08 | -0.26 | -0.07 | -0.07 | -0.28 | -0.64 | -0.26 | -0.35 |
| Free Cash Flow | -35.99 | 3.96 | -8.68 | -8.64 | -7.02 | -9.88 | -30.08 | -17.87 | -3.90 | -28.58 |
| Cash & Equivalents | 11.73 | 8.07 | 60.69 | 38.93 | 39.95 | 47.15 | 53.50 | 83.86 | 50.43 | 55.27 |
| Total Debt | 0.07 | 4.64 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 11.66 | 3.43 | 60.69 | 38.93 | 39.95 | 47.15 | 53.50 | 83.86 | 50.43 | 55.27 |
| Assets | 18.14 | 8.75 | 80.49 | 52.28 | 49.91 | 57.98 | 66.35 | 96.52 | 68.77 | 72.91 |
| Liabilities | 10.57 | 22.08 | 16.92 | 7.15 | 4.52 | 6.06 | 4.94 | 7.44 | 8.43 | 8.55 |
| Book Value | 7.57 | -71.62 | 63.58 | 45.14 | 45.39 | 51.92 | 61.41 | 89.09 | 60.35 | 64.36 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Brickell Biotech, Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
Robert B. Brown |
Stock Information
| Ticker Symbol |
BBI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BBI |
Description
Brickell Biotech, a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. Brickell Biotech, Inc. has collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19 in the United States. The company was founded in 2009 and is based in Boulder, Colorado.